Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AC Immune S.A. (NQ: ACIU )

2.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.380
Bid (Size) 1.230 (6)
Ask (Size) 2.990 (6)
Prev. Close 2.380
Today's Range 2.380 - 2.380
52wk Range 1.680 - 4.840
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
From AC Immune SA
Via Globe NewsWire
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
From AC Immune SA
Via Globe NewsWire

Performance

YTD
+7.69%
+7.69%
1 Month
+3.93%
+3.93%
3 Month
+30.05%
+30.05%
6 Month
-27.66%
-27.66%
1 Year
-43.33%
-43.33%

More News

Read More
AC Immune Earnings Preview
Via Benzinga
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
From AC Immune SA
Via Globe NewsWire
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
From AC Immune SA
Via Globe NewsWire
AC Immune to Present at the SVB Securities Global Biopharma Conference
From AC Immune SA
Via Globe NewsWire
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
From AC Immune SA
Via Globe NewsWire
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
From AC Immune SA
Via Globe NewsWire
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
From AC Immune SA
Via Globe NewsWire
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
From AC Immune SA
Via Globe NewsWire
Is Ardelyx is A Buy After Slip in Early 2022
Via MarketBeat
Exposures Product Safety
AC Immune: Q3 Earnings Insights
Via Benzinga
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Why Zoom Video Is Trading Lower By 11%; Here Are 28 Stocks Moving Premarket
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide
Via Benzinga
63 Biggest Movers From Yesterday
Via Benzinga
Mid-Day Market Update: Dow Tumbles 700 points; Advent Technologies Shares Spike Higher
Via Benzinga
37 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.